These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 34453556)

  • 1. To establish a model for the prediction of initial standard and maintenance doses of warfarin for the Han Chinese population based on gene polymorphism: a multicenter study.
    Xia X; Huang N; Li B; Li Y; Zou L; Yuan D; Huang B; Bei Y; Liu Y; Fu J; Wu T; Chen W; Jiang S; Lv M; Zhang J
    Eur J Clin Pharmacol; 2022 Jan; 78(1):43-51. PubMed ID: 34453556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of warfarin maintenance dose in Han Chinese patients using a mechanistic model based on genetic and non-genetic factors.
    Lu Y; Yang J; Zhang H; Yang J
    Clin Pharmacokinet; 2013 Jul; 52(7):567-81. PubMed ID: 23515956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients.
    Liang R; Li L; Li C; Gao Y; Liu W; Hu D; Sun Y
    J Thromb Thrombolysis; 2012 Jul; 34(1):120-5. PubMed ID: 22528326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with atrial fibrillation and valve replacement.
    Chen W; Wu L; Liu X; Shen Y; Liang Y; Zhu J; Tan H; Yang Y; Liu Q; Wang M; Liu L; Wang X
    Int J Clin Pharmacol Ther; 2017 Feb; 55(2):126-132. PubMed ID: 27117036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VKORC1 and CYP2C9 genotypic data-based dose prediction alone does not accurately predict warfarin dose requirements in some Malaysian patients.
    Chua YA; Abdullah WZ; Yusof Z; Gan SH
    Turk J Med Sci; 2015; 45(4):913-8. PubMed ID: 26422867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation.
    Wei M; Ye F; Xie D; Zhu Y; Zhu J; Tao Y; Yu F
    Thromb Haemost; 2012 Jun; 107(6):1083-91. PubMed ID: 22534826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
    Miao L; Yang J; Huang C; Shen Z
    Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.
    Cen HJ; Zeng WT; Leng XY; Huang M; Chen X; Li JL; Huang ZY; Bi HC; Wang XD; He YL; He F; Zhou RN; Zheng QS; Zhao LZ
    Br J Clin Pharmacol; 2010 Aug; 70(2):234-40. PubMed ID: 20653676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of sensitivity to warfarin based on VKORC1 and CYP2C9 polymorphisms in patients from different places in Colombia.
    Cifuentes RA; Murillo-Rojas J; Avella-Vargas E
    Biomedica; 2016 Mar; 36(1):91-100. PubMed ID: 27622442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VKORC1-1639G>A, CYP2C9, EPHX1691A>G genotype, body weight, and age are important predictors for warfarin maintenance doses in patients with mechanical heart valve prostheses in southwest China.
    Gu Q; Kong Y; Schneede J; Xiao YB; Chen L; Zhong QJ; Wang XF; Hao J; Chen BC; Chen JJ
    Eur J Clin Pharmacol; 2010 Dec; 66(12):1217-27. PubMed ID: 20842355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
    Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR
    Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients.
    Ohno M; Yamamoto A; Ono A; Miura G; Funamoto M; Takemoto Y; Otsu K; Kouno Y; Tanabe T; Masunaga Y; Nonen S; Fujio Y; Azuma J
    Eur J Clin Pharmacol; 2009 Nov; 65(11):1097-103. PubMed ID: 19582440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of Renal Impairment and Genetic Subtypes on Warfarin Control in Japanese Patients.
    Tanaka T; Ihara M; Fukuma K; Yamamoto H; Washida K; Kimura S; Kada A; Miyata S; Miyata T; Nagatsuka K
    Genes (Basel); 2021 Sep; 12(10):. PubMed ID: 34680932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.
    Ozer N; Cam N; Tangurek B; Ozer S; Uyarel H; Oz D; Guney MR; Ciloglu F
    Heart Vessels; 2010 Mar; 25(2):155-62. PubMed ID: 20339978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism.
    Bazan NS; Sabry NA; Rizk A; Mokhtar S; Badary OA
    Ir J Med Sci; 2014 Jun; 183(2):161-72. PubMed ID: 23800980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics of Warfarin in a Diverse Patient Population.
    Mak M; Lam C; Pineda SJ; Lou M; Xu LY; Meeks C; Lin C; Stone R; Rodgers K; Mitani G
    J Cardiovasc Pharmacol Ther; 2019 Nov; 24(6):521-533. PubMed ID: 31064211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic Associations With Stable Warfarin Dose Requirements in Han Chinese Patients.
    Xu Q; Zhang S; Wu C; Xiong Y; Niu J; Li F; Zhu J; Shen L; Zhu B; Xing Q; He L; Chen L; Li M; Li H; Ge J; Qin S
    J Cardiovasc Pharmacol; 2021 Jul; 78(1):e105-e111. PubMed ID: 33958549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
    Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
    J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation.
    Santos PC; Dinardo CL; Schettert IT; Soares RA; Kawabata-Yoshihara L; Bensenor IM; Krieger JE; Lotufo PA; Pereira AC
    Eur J Clin Pharmacol; 2013 Apr; 69(4):789-97. PubMed ID: 22990331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetic impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate.
    Palacio L; Falla D; Tobon I; Mejia F; Lewis JE; Martinez AF; Arcos-Burgos M; Camargo M
    Clin Appl Thromb Hemost; 2010 Feb; 16(1):83-90. PubMed ID: 19567378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.